Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Considers Mapping Generic Drug Complaints To Spot Safety Trends

Executive Summary

A cluster of complaints in one area may inform a new safety signal or other problem, agency official says.

You may also be interested in...



Checkpoint Inhibitors: US FDA Wants Consistent Adverse Event Definitions

Label writing is difficult because sponsors are collecting varying adverse reaction data, agency officials say.

US FDA Sets Generic Approval Record, But Generic Sponsors Aren't Celebrating

FDA relates new record to its plan to increase access to affordable drugs, but Association for Accessible Medicines says approvals alone will not increase competition.

New CDER No. 2 May Impact FDA's Safety Monitoring Aspirations

Patrizia Cavazzoni, CDER's new deputy director for operations, has safety surveillance background and wants to see FDA continue to grow its capabilities.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS124674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel